MS patients share their shot experiences: kesimpta vs ocrevus

NCT ID NCT06668324

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study looked at how people with multiple sclerosis felt about their first injection of either Kesimpta or a new under-the-skin version of Ocrevus. Researchers asked 134 adults about pain, redness, swelling, and itching at the injection site, as well as overall satisfaction. The goal was to understand which treatment might be easier or more comfortable for patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative site

    East Hanover, New Jersey, 07936, United States

Conditions

Explore the condition pages connected to this study.